Financial Performance - The company's total revenue for the year ended December 31, 2022, was RMB 585.88 million, representing a 26.08% increase compared to RMB 464.68 million in 2021[2] - Gross profit for the same period was RMB 332.49 million, with a gross margin decrease from approximately 59.34% in 2021 to about 56.75% in 2022[3] - Net profit for the year was RMB 133.83 million, a decrease of 4.71% from RMB 140.45 million in the previous year[3] - Basic earnings per share (EPS) were RMB 0.79, down 8.14% from RMB 0.86 in 2021, while diluted EPS was RMB 0.78, down 9.30% from RMB 0.86[3] - Total revenue for the year ended December 31, 2022, was RMB 585,883,000, an increase from RMB 464,675,000 in 2021, representing a growth of approximately 26%[14] - Net profit for 2022 was RMB 133,833,000, a decrease of 4.4% compared to RMB 140,445,000 in 2021[21] Revenue Breakdown - Revenue from cardiovascular devices was RMB 483,059,000 in 2022, up from RMB 427,163,000 in 2021, indicating a growth of about 13%[14] - Revenue from neuro and peripheral devices increased significantly to RMB 19,755,000 in 2022 from RMB 7,123,000 in 2021, marking a growth of approximately 178%[14] - The company generated RMB 437,344,000 from mainland China in 2022, compared to RMB 361,762,000 in 2021, reflecting a growth of around 21%[16] - The company reported a total of RMB 497,054,000 in revenue from the heart intervention business for 2022, compared to RMB 411,178,000 in 2021, representing an increase of approximately 21%[20] - The company’s revenue from agency business rose to RMB 50,325,000 in 2022 from RMB 13,997,000 in 2021, showing a growth of about 260%[14] - The total revenue from other segments was RMB 133,262,000 in 2022, compared to RMB 81,732,000 in 2021, indicating an increase of approximately 63%[20] Assets and Liabilities - The company's total assets as of December 31, 2022, were RMB 1,587.67 million, compared to RMB 1,468.32 million at the end of 2021[8] - Current assets increased to RMB 1,025.39 million in 2022 from RMB 763.11 million in 2021[8] - The company's net current assets decreased to RMB 562.28 million in 2022 from RMB 705.22 million in 2021[8] - Non-current liabilities increased to RMB 33.57 million in 2022 from RMB 30.40 million in 2021[10] - Total equity rose to RMB 1,554.10 million in 2022, up from RMB 1,437.92 million in 2021[10] Research and Development - R&D expenses for 2022 amounted to RMB 140,941,000, up from RMB 109,801,000 in 2021, reflecting a 28.3% increase[26] - The R&D team consists of professionals with over 10 years of experience, holding 260 registered patents and 184 pending applications as of December 31, 2022[50] - The company plans to further develop its product pipeline and increase R&D investment in 2023, focusing on core product development and new product certification[59] Employee and Operational Costs - Employee costs for 2022 totaled RMB 190,667,000, a significant rise from RMB 133,925,000 in 2021, marking an increase of 42.3%[23] - The cost of goods sold for 2022 was RMB 253,397,000, compared to RMB 188,930,000 in 2021, indicating a 34.2% increase[26] - Distribution costs increased by approximately 87.85% to RMB 56.39 million, compared to RMB 30.02 million for the year ended December 31, 2021, accounting for about 9.63% of total revenue[65] - Administrative expenses for the reporting period were approximately RMB 64.29 million, up from approximately RMB 49.05 million for the year ended December 31, 2021, primarily due to increased salaries and other compensation related to business expansion[66] Dividends and Shareholder Information - The board proposed a final dividend of RMB 0.24 per share for the year ended December 31, 2022[3] - The company plans to declare a final dividend of RMB 0.24 per share for 2022, down from RMB 0.26 per share in 2021[44] - The group proposed a final dividend of RMB 0.24 per share for the year ended December 31, 2022, compared to RMB 0.26 per share for the year ended December 31, 2021[72] Compliance and Governance - The audit committee has reviewed the company's audited consolidated annual results and confirmed compliance with applicable accounting principles and regulations[90] - The preliminary financial figures for the year ending December 31, 2022, have been confirmed to be consistent with the audited consolidated financial statements by KPMG[91] - The company has adopted a code of conduct for securities transactions by directors and supervisors, confirming compliance during the reporting period[87] Future Plans and Investments - The company plans to invest RMB 156.33 million (19.60%) in the construction of the Shandong Yingtai Innovation Medical Devices Industrial Park, with a projected completion date of June 2024[76] - The company has committed to invest RMB 50 million in the Chengdu Huige Guosheng Venture Capital Partnership by June 30, 2026[37] - The company has established a partnership to invest RMB 50 million in the Chengdu Huai Ge Fund, targeting early-stage or growth-stage companies in the medical and biotechnology sectors[58]
康德莱医械(01501) - 2022 - 年度业绩